NCT03223649

Brief Summary

Background: Some studies have found that people can better process sugars when they take walking breaks. Studies have also found that children's attention and memory may improve after exercise. It is not known if short walking breaks have the same effects. Researchers want to study if breaking up sitting with walking for 6 days helps children s bodies use sugars and improves concentration. Objectives: To learn if breaking up sedentary (low-activity) time with short walking breaks over 6 days affects how children s bodies use sugar. To learn if breaking up sedentary time changes children s attention, memory, feelings, activity, or eating. Eligibility: Children ages 7-11 in general good health Design: Participants will be screened with:

  • Medical history
  • Physical exam
  • Fasting blood tests. On 2 out of 7 total study visits, participants cannot eat or drink after 10 p.m. the night before.
  • Full-body X-ray
  • EKG (Electronic signals that record heart function through stickers)
  • Treadmill exercise. Heart, blood pressure, and oxygen will be monitored.
  • Questions about the child s health, socialization, and activity, and parent s education and economic status
  • Picture vocabulary test
  • Dietician meeting (Questions about eating habits) Participants will have visits on 6 consecutive days. Over that time, they will wear 2 devices to monitor blood sugar and activity (even while at home). Participants will have 5 after-school visits. These include:
  • Health check
  • Snack plus food for the next 24 hours
  • Activity monitored
  • 3-hour sitting tests. Participants will do non-active things. Some will have 3-minute walks every 30 minutes.
  • Cognitive tests and questions about mood and anxiety are given on days #1 \& 5. Participants will fast before the last visit in the morning. They will have:
  • 9 blood draws by IV catheter. Participants will drink sugar water.
  • Sitting test
  • Activity monitored
  • Meal (food buffet)

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
129

participants targeted

Target at P50-P75 for phase_2 healthy

Timeline
Completed

Started Jul 2017

Longer than P75 for phase_2 healthy

Geographic Reach
1 country

1 active site

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

July 19, 2017

Completed
2 days until next milestone

First Posted

Study publicly available on registry

July 21, 2017

Completed
5 days until next milestone

Study Start

First participant enrolled

July 26, 2017

Completed
2.9 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

June 26, 2020

Completed
8 months until next milestone

Study Completion

Last participant's last visit for all outcomes

February 23, 2021

Completed
4 months until next milestone

Results Posted

Study results publicly available

June 11, 2021

Completed
Last Updated

June 11, 2021

Status Verified

January 4, 2021

Enrollment Period

2.9 years

First QC Date

July 19, 2017

Results QC Date

April 25, 2021

Last Update Submit

May 13, 2021

Conditions

Keywords

MetabolismChildrenWalking BoutsGlucoseInsulin

Outcome Measures

Primary Outcomes (1)

  • Insulin iAUC Obtained During the Oral Glucose Tolerance Test at the Final Experimental Visit.

    Insulin integrated area under the curve (iAUC) as a marker of glucose metabolism on OGTT during test day #6, collected at 0, 30, 60, 90, 120, 150, and 180 minutes after oral dextrose ingestion

    test day 6

Secondary Outcomes (9)

  • Glucose iAUC Obtained During the Oral Glucose Tolerance Test on Day # 6 of Intervention.

    test day 6

  • C-Peptide iAUC Obtained During the Oral Glucose Tolerance Test on Day # 6 of Intervention.

    test day 6

  • Free Fatty Acid iAUC Obtained During the Oral Glucose Tolerance Test on Day # 6 of Intervention.

    test day 6

  • Daily Physical Activity (Step Counts/Min) During Intervention.

    test days 1-6

  • Daily Physical Activity (3-dimensional Activity Counts/Day) Outside of the Intervention.

    test days 1-6

  • +4 more secondary outcomes

Study Arms (2)

Sedentary

EXPERIMENTAL

(Control intervention) Six daily 3 hour sessions with no physical activity (i.e. subject remains sedentary in seated or recumbent position) throughout the 3 hour duration.

Other: Sedentary

Walking bouts

EXPERIMENTAL

Six daily 3 hour sessions with prompted 3-minute moderate-intensity walking bouts performed on a treadmill every 30 minutes throughout the 3 hour duration. There will be a total of 6 walking bouts (18 minutes total) each day. Moderate-intensity walking speed and grade will be selected to achieve 80% of the heart rate achieved at the ventilatory threshold as determined during a V02max test.

Other: Walking Bouts

Interventions

Six daily 3 hour sessions with prompted 3-minute moderate-intensity walking bouts performed on a treadmill every 30 minutes throughout the 3 hour duration. There will be a total of 6 walking bouts (18 minutes total) each day. Moderate-intensity walking speed and grade will be selected to achieve 80% of the heart rate achieved at the ventilatory threshold as determined during a V02max test.

Walking bouts

(Control 'intervention') Six daily 3 hour sessions with no physical activity (i.e. subject remains sedentary in seated or recumbent position) throughout the 3 hour duration.

Sedentary

Eligibility Criteria

Age7 Years - 11 Years
Sexall
Healthy VolunteersNo
Age GroupsChild (0-17)

You may qualify if:

  • Participants will qualify for the study if they meet the following criteria:
  • Good general health.
  • Age greater than or equal to 7 and less than 12 years.
  • Fasting plasma glucose less than 100 mg/dL
  • Body mass index (BMI) greater than or equal to the 5th percentile, as determined by the CDC age- and sex- specific growth charts.

You may not qualify if:

  • Participants will be excluded from the study for:
  • Significant cardiac or pulmonary disease likely to or resulting in hypoxia or decreased perfusion.
  • Evidence of impaired glucose tolerance or type 2 diabetes, including fasting plasma glucose greater than or equal to 100 mg/dL.
  • Presence of other endocrinologic disorders leading to obesity (e.g.: Cushing Syndrome).
  • Participants who have, or whose parent/guardians have, current substance abuse or a psychiatric disorder or other condition that, in the opinion of the investigators, would impede competence, compliance, or prevent the completion of the study.
  • Participants who have, or are currently receiving, anti-psychotic drugs that would affect metabolism, cognitive outcomes, and body habitus.
  • Participants receiving medical treatment other than diet for hypertension or dyslipidemia.
  • Participants with precocious puberty and/or receiving androgen and estrogen therapy.
  • Participants currently taking medications for ADHD, or any disorder or use of medications known to affect body composition or weight including but not limited to glucocorticoids or other steroid compounds.
  • Presence of pre-existing neurocognitive disabilities, or an age-adjusted score below 85 on the Picture Vocabulary Test at the screening visit.
  • Presence of food allergies, such as peanut/tree nut, dairy, soy or any other food allergy or personal dietary restrictions that would preclude participant from consuming the daily diet or the buffet.
  • Presence of significant skin disease or allergy to adhesive material prohibiting placement of a continuous glucose monitor.
  • Participants unable or unwilling to abstain from acetaminophen, ascorbic acid, or salicylic acid during study duration.
  • Participant does not speak fluent English.
  • Participant is or becomes pregnant.
  • +16 more criteria

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

National Institutes of Health Clinical Center

Bethesda, Maryland, 20892, United States

Location

Related Publications (3)

  • Broadney MM, Belcher BR, Berrigan DA, Brychta RJ, Tigner IL Jr, Shareef F, Papachristopoulou A, Hattenbach JD, Davis EK, Brady SM, Bernstein SB, Courville AB, Drinkard BE, Smith KP, Rosing DR, Wolters PL, Chen KY, Yanovski JA. Effects of Interrupting Sedentary Behavior With Short Bouts of Moderate Physical Activity on Glucose Tolerance in Children With Overweight and Obesity: A Randomized Crossover Trial. Diabetes Care. 2018 Oct;41(10):2220-2228. doi: 10.2337/dc18-0774. Epub 2018 Aug 6.

    PMID: 30082324BACKGROUND
  • Belcher BR, Berrigan D, Papachristopoulou A, Brady SM, Bernstein SB, Brychta RJ, Hattenbach JD, Tigner IL Jr, Courville AB, Drinkard BE, Smith KP, Rosing DR, Wolters PL, Chen KY, Yanovski JA. Effects of Interrupting Children's Sedentary Behaviors With Activity on Metabolic Function: A Randomized Trial. J Clin Endocrinol Metab. 2015 Oct;100(10):3735-43. doi: 10.1210/jc.2015-2803. Epub 2015 Aug 27.

    PMID: 26312582BACKGROUND
  • Dunstan DW, Kingwell BA, Larsen R, Healy GN, Cerin E, Hamilton MT, Shaw JE, Bertovic DA, Zimmet PZ, Salmon J, Owen N. Breaking up prolonged sitting reduces postprandial glucose and insulin responses. Diabetes Care. 2012 May;35(5):976-83. doi: 10.2337/dc11-1931. Epub 2012 Feb 28.

    PMID: 22374636BACKGROUND

Related Links

MeSH Terms

Conditions

ObesityOverweightInsulin Resistance

Condition Hierarchy (Ancestors)

OvernutritionNutrition DisordersNutritional and Metabolic DiseasesBody WeightSigns and SymptomsPathological Conditions, Signs and SymptomsHyperinsulinismGlucose Metabolism DisordersMetabolic Diseases

Results Point of Contact

Title
Jack A. Yanovski, MD, PhD
Organization
National Institutes of Health

Study Officials

  • Jack A Yanovski, M.D.

    Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)

    PRINCIPAL INVESTIGATOR

Publication Agreements

PI is Sponsor Employee
No
Restrictive Agreement
No

Study Design

Study Type
interventional
Phase
phase 2
Allocation
RANDOMIZED
Masking
NONE
Purpose
PREVENTION
Intervention Model
PARALLEL
Sponsor Type
NIH
Responsible Party
SPONSOR

Study Record Dates

First Submitted

July 19, 2017

First Posted

July 21, 2017

Study Start

July 26, 2017

Primary Completion

June 26, 2020

Study Completion

February 23, 2021

Last Updated

June 11, 2021

Results First Posted

June 11, 2021

Record last verified: 2021-01-04

Data Sharing

IPD Sharing
Will share

Individual level deidentified data for all sociodemographic characteristics and outcomes will be made available after publication of the study primary outcome.

Shared Documents
STUDY PROTOCOL, ICF
Time Frame
Immediately following publication of the primary outcome for 5 years
Access Criteria
A data sharing agreement may have to be negotiated with NICHD. Contact Dr. Jack Yanovski jy15i@nih.gov, 301-496-0858.

Locations